BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

Performant Healthcare, Inc. (Nasdaq: PHLT) ("Performant"), a leading provider of technology-enabled payment integrity, eligibility, and related analytics services, announced today that it will ...

The deal priced below last closing price of $8.44. BTIG is acting as lead book running manager for the offering. Published first on TheFly – the ...

BTIG Research lowered shares of IQVIA (NYSE:IQV – Free Report) from a buy rating to a neutral rating in a research report report published on Monday morning, Marketbeat.com reports. Several other ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

BTIG Research has recently reduced MGM Resorts International (MGM) stock to Neutral rating, as announced on February 3, 2025, according to Finviz. Earlier, on July 3, 2024, BTIG Research had initiated ...

InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, ...

BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and ...

What damage might Monday's ongoing selloff do to the technical set-up for stocks? Well, in a note published on Sunday, BTIG chartist guru Jonathan Krinsky observed that Friday's action had already sug ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...